08:51 AM EDT, 09/24/2024 (MT Newswires) -- Silexion Therapeutics ( SLXN ) said Tuesday patients with non-resectable locally advanced pancreatic cancer whose pancreatic cancer tumors became resectable had a 67% objective response rate in a phase 2 trial of its experimental drug Loder.

The trial showed an overall 56% objective response rate among patients with non-resectable locally advanced pancreatic cancer.

Previously, Silexion reported that Loder combined with standard of care chemotherapy improved overall survival in patients by 9.3 months compared with chemotherapy alone.

Shares of the company rose 18% in recent Tuesday premarket activity.

Price: 0.9450, Change: +0.15, Percent Change: +18.14